9:00am - 5:00pm

Office Hours Mon. - Fri.

800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Archive

Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors

ConditionCervical Cancer|Fallopian Tube Cancer|Head and Neck Cancer|Lung Cancer|Malignant Mesothelioma|Ovarian Cancer|Pancreatic Cancer|Primary Peritoneal Cavity CancerEstimated Enrollment: nullAge Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: CDR0000316451|NCI-03-C-0243|NCI-6221|NCI-SS1PE-002Study First Received: August 6, 2003Last Updated: April 29, 2015Estimated Primary Completion Date: nullPrimary Outcome Measures:Sponsors and Collaborators:National Cancer Institute (NCI)Result Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00066651...

Continue reading

Immunotoxin Therapy in Treating Patients With Advanced Cancer

ConditionCervical Cancer|Fallopian Tube Cancer|Head and Neck Cancer|Lung Cancer|Malignant Mesothelioma|Ovarian Cancer|Pancreatic Cancer|Primary Peritoneal Cavity CancerEstimated Enrollment: nullAge Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: CDR0000068351|NCI-01-C-0011|NCI-6249Study First Received: December 6, 2000Last Updated: April 29, 2015Estimated Primary Completion Date: nullPrimary Outcome Measures:Sponsors and Collaborators:National Cancer Institute (NCI)Result Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00006981...

Continue reading

Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors

ConditionAdrenocortical Carcinoma|Brain and Central Nervous System Tumors|Head and Neck Cancer|Liver Cancer|Malignant Mesothelioma|Pheochromocytoma|SarcomaEstimated Enrollment: 30Age Group: up to 65 Years   (Child, Adult)Gender: AllStudy Type: InterventionalStudy Design Allocation: Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: CAN-OTT-9401|CDR0000063892|NCI-V94-0566Study First Received: November 1, 1999Last Updated: July 9, 2013Estimated Primary Completion Date: nullPrimary Outcome Measures:Sponsors and Collaborators:Ottawa Regional Cancer Centre|National Cancer Institute (NCI)Result Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00002608...

Continue reading

Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer

ConditionBreast Cancer|Colorectal Cancer|Kidney Cancer|Lung Cancer|Malignant Mesothelioma|Pancreatic CancerEstimated Enrollment: 40Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Primary Purpose: TreatmentStudy ID Numbers: SVMC-ONC-222|CDR0000076913|NCI-V91-0075Study First Received: November 1, 1999Last Updated: July 9, 2013Estimated Primary Completion Date: December 2007Primary Outcome Measures:Clinical response (patients with evaluable disease)|Duration of response (patients with evaluable disease)|Survival (patients with evaluable disease)|Time to recurrence (patients without evaluable disease)|Survival (patients without evaluable disease)Sponsors and Collaborators:St. Vincent Medical Center - Los Angeles|National Cancer Institute (NCI)Result Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00002475...

Continue reading

Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors

ConditionBreast Cancer|Colorectal Cancer|Head and Neck Cancer|Lung Cancer|Mesothelioma|Pancreatic Cancer|Prostate Cancer|SarcomaEstimated Enrollment: 16Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: 2007LS086|0712M22703Study First Received: June 20, 2008Last Updated: November 6, 2012Estimated Primary Completion Date: September 2010Primary Outcome Measures:Maximum tolerated dose of sorafenib tosylate|Disease Response|Maximum, Minimum and AUC Concentrations of SorafenibSponsors and Collaborators:Masonic Cancer Center, University of MinnesotaResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00703638...

Continue reading

Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

ConditionAdvanced Malignant Mesothelioma|Carcinoma of the Appendix|Ovarian Sarcoma|Ovarian Stromal Cancer|Pseudomyxoma Peritonei|Recurrent Colon Cancer|Recurrent Malignant Mesothelioma|Recurrent Ovarian Epithelial Cancer|Recurrent Ovarian Germ Cell Tumor|Stage III Colon Cancer|Stage III Ovarian Epithelial Cancer|Stage III Ovarian Germ Cell Tumor|Stage IV Colon Cancer|Stage IV Ovarian Epithelial Cancer|Stage IV Ovarian Germ Cell Tumor|Unspecified Childhood Solid Tumor, Protocol SpecificEstimated Enrollment: 10Age Group: Child, Adult, SeniorGender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive CareStudy ID Numbers: CCCWFU 97110|NCI-2010-00980Study First Received: May 13, 2010Last Updated: January 17, 2017Estimated Primary Completion Date: April 2011Primary Outcome Measures:Assess feasibility of instituting an orientation program, brief follow up...

Continue reading

Study of Pemetrexed and Bevacizumab in Patients With Head and Neck Cancer

ConditionCancerEstimated Enrollment: 42Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: 05-002|12,158Study First Received: September 16, 2005Last Updated: January 15, 2016Estimated Primary Completion Date: October 2013Primary Outcome Measures:Time-to-progression (TTP)|Objective Response Rate (ORR)|Disease Control Rate (DCR)|Overall Survival (OS)Sponsors and Collaborators:University of Pittsburgh|Eli Lilly and Company|Genentech, Inc.Result Received: January 15, 2016Website Link: https://ClinicalTrials.gov/show/NCT00222729...

Continue reading

A Dose Escalation Study to Assess Safety of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumors

ConditionCancerEstimated Enrollment: 34Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: 114746Study First Received: September 5, 2013Last Updated: January 16, 2017Estimated Primary Completion Date: June 2016Primary Outcome Measures:Part 1: Safety assessment as assessed by adverse events (AEs) and serious adverse events (SAEs)|Part 1: Safety assessment as assessed by 12-lead electrocardiogram (ECG)|Part 1: Safety assessment as assessed by vital signs|Part 1: Safety assessment as assessed by change from baseline in laboratory values|Part 1: Safety assessment as assessed by echocardiogram|Part 1: Safety assessment as assessed...

Continue reading

Thrombin Generation and Platelet Activation in CRS/HIPEC

ConditionMesothelioma; Peritoneum|Pseudomyxoma Peritonei|Peritoneal CarcinomatosisEstimated Enrollment: 27Age Group: up to 80 Years   (Child, Adult, Senior)Gender: AllStudy Type: ObservationalStudy Design Allocation: Observational Model: Cohort|Time Perspective: ProspectiveStudy ID Numbers: B37120154199Study First Received: January 12, 2017Last Updated: January 24, 2017Estimated Primary Completion Date: July 2016Primary Outcome Measures:Blood loss|Red blood cell count|White blood cell count|Platelet count|Fibrinogen levels|Prothrombin Time (PT)|Activated Partial Thromboplastin Time (aPTT)|Endogenous Thrombin Potential (Thrombin generation assay (CAT))|Lag Time (Thrombin generation assay (CAT))|Time-to-Thrombin Peak (Thrombin generation assay (CAT))|Thrombin Peak (TP) (Thrombin generation assay (CAT))|P-selectin expression (Platelet activation test (PACT))|αIIbβ3 activation (Platelet activation test (PACT))|A5 EXTEM (Rotational thromboelastometry (ROTEM))|A5 FIBTEM (Rotational thromboelastometry (ROTEM))|A5 HEPTEM...

Continue reading

Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer

ConditionLung Cancer|Malignant Mesothelioma|Metastatic Cancer|Thymoma and Thymic CarcinomaEstimated Enrollment: 30Age Group: Child, Adult, SeniorGender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: CDR0000068889|P30CA016042|UCLA-9908024|NCI-G01-2011Study First Received: September 13, 2001Last Updated: October 28, 2015Estimated Primary Completion Date: December 2006Primary Outcome Measures:Sponsors and Collaborators:Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)Result Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00024076...

Continue reading